CA3230155A1 - Polytherapie a base d'un antagoniste de l'hormone de croissance et d'une composition anticancereuse - Google Patents

Polytherapie a base d'un antagoniste de l'hormone de croissance et d'une composition anticancereuse Download PDF

Info

Publication number
CA3230155A1
CA3230155A1 CA3230155A CA3230155A CA3230155A1 CA 3230155 A1 CA3230155 A1 CA 3230155A1 CA 3230155 A CA3230155 A CA 3230155A CA 3230155 A CA3230155 A CA 3230155A CA 3230155 A1 CA3230155 A1 CA 3230155A1
Authority
CA
Canada
Prior art keywords
cancer
composition
growth hormone
human growth
hormone receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3230155A
Other languages
English (en)
Inventor
Richard S. Brody
Thomas J. Zupancic
Uday Sandbhor
John J. Kopchick
Reetobrata BASU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Technologies Laboratories LLC
Original Assignee
Molecular Technologies Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/411,497 external-priority patent/US11857602B2/en
Application filed by Molecular Technologies Laboratories LLC filed Critical Molecular Technologies Laboratories LLC
Publication of CA3230155A1 publication Critical patent/CA3230155A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pour le traitement d'une maladie ou d'un état réactif à des antagonistes du récepteur de l'hormone de croissance humaine, comprenant un antagoniste du récepteur de l'hormone de croissance humaine modifiée ; et une composition anticancéreuse. L'invention concerne également une méthode de traitement du cancer à l'aide d'antagonistes de l'hormone de croissance humaine, comprenant le pré-criblage d'un patient par analyse d'une biopsie de tumeur pour confirmer la présence d'un cancer et la présence de certains facteurs prédéterminés indicatifs de la réactivité à des antagonistes de l'hormone de croissance humaine ; et le traitement du patient avec une quantité efficace d'une composition qui comprend un antagoniste du récepteur de l'hormone de croissance humaine modifiée et une composition anticancéreuse.
CA3230155A 2021-08-25 2022-08-15 Polytherapie a base d'un antagoniste de l'hormone de croissance et d'une composition anticancereuse Pending CA3230155A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/411,497 2021-08-25
US17/411,497 US11857602B2 (en) 2019-06-17 2021-08-25 Growth hormone antagonist and anti-cancer composition combination therapy
PCT/US2022/074968 WO2023028430A2 (fr) 2021-08-25 2022-08-15 Polythérapie à base d'un antagoniste de l'hormone de croissance et d'une composition anticancéreuse

Publications (1)

Publication Number Publication Date
CA3230155A1 true CA3230155A1 (fr) 2023-03-02

Family

ID=85323353

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3230155A Pending CA3230155A1 (fr) 2021-08-25 2022-08-15 Polytherapie a base d'un antagoniste de l'hormone de croissance et d'une composition anticancereuse

Country Status (2)

Country Link
CA (1) CA3230155A1 (fr)
WO (1) WO2023028430A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098137A1 (en) * 2006-04-05 2009-04-16 Novartis Ag Combinations of therapeutic agents for treating cancer
US20100166747A1 (en) * 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists
US11473088B2 (en) * 2016-12-02 2022-10-18 Ohio University Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
JP2022536788A (ja) * 2019-06-17 2022-08-18 モレキュラー テクノロジーズ ラボラトリーズ エルエルシー Ｐｅｇ化された成長ホルモンアンタゴニストの治療薬

Also Published As

Publication number Publication date
WO2023028430A3 (fr) 2023-04-06
WO2023028430A2 (fr) 2023-03-02

Similar Documents

Publication Publication Date Title
Lu et al. Targeting growth hormone function: strategies and therapeutic applications
JP6776380B2 (ja) 癌モデル及び関連方法
Watt et al. Biology of somatostatin in breast cancer
Khandwala et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
CA2654944C (fr) Polypeptides du facteur de croissance de type insuline stabilises
Zhou et al. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion
Yin et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy
US20060058224A1 (en) Methods of treating obesity with combination therapeutics
Ferone et al. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation
AU3839400A (en) Proliferation inhibitor for androgen-independent tumor
Ovejero et al. Octreotide is ineffective in treating tumor‐induced osteomalacia: results of a short‐term therapy
Maia et al. Novel therapies for acromegaly
JP2024016080A (ja) Ｐｅｇ化された成長ホルモンアンタゴニストの治療薬
US11857602B2 (en) Growth hormone antagonist and anti-cancer composition combination therapy
CA3230155A1 (fr) Polytherapie a base d'un antagoniste de l'hormone de croissance et d'une composition anticancereuse
CN114957491B (zh) 一种靶向结合β-catenin蛋白的多肽、多肽衍生物及其应用
RU2726254C2 (ru) Блокаторы рецептора гормона роста при предупреждении заболеваний и лечении
US11091517B2 (en) Peptide derivative and pharmaceutical composition containing same
US20210169984A1 (en) Sensitizing cancer to death receptor agonists with kinase inhibitors
EP3326624A1 (fr) Immunothérapie pour le cancer exprimant le casr (par ex., neuroblastome)
EP3984547A1 (fr) Peptides pour le traitement du cancer
EP4122467A1 (fr) Thx-b pour le traitement et la prévention du cancer et des métastases
England et al. Somatostatins and their role in thyroid cancer
JP2020521723A (ja) 悪液質の診断方法および治療方法
Herrera-Martínez et al. Partially based on: Neuroendocrine tumors: diagnostic, predictive and prognostic markers Aura D Herrera-Martínez., Leo J. Hofland1, Wouter W. de Herder1, María A. Gálvez Moreno2, Justo P. Castaño2 and Richard A. Feelders1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240222

EEER Examination request

Effective date: 20240222